Faculty Bibliography

Cochlear implants are electrical prostheses that partially replace the functions of the human ear. They bypass normal hearing operation to directly simulate the auditory nerve with electric current. The input acoustic signal passes through a filter bank and the output of each filter modulates the energy of a stimulation waveform delivered to a different intra-cochlear electrode. This approach attempts to mimic the signal processing that takes place in a normal ear. When fitting a cochlear implant to a patient who has lost his hearing after learning language, one important problem is how to optimize the frequency range of the filter bank This optimization seeks a tradeoff between maximum speech perception and the patient\\\\\\\'s subjective preference. Unfortunately, currently available tools to change the frequency-to-electrode mapping (i.e., the frequencies of the filter bank) are cumbersome to use. In a previous project we developed a real time speech processor for the Nucleus-22 and Nucleus-24 cochlear implants, based on a common PC and additional hardware drivers. The present project involves the development of a similar system that is adjustable in real time. In other words, the patient can modify the frequency-to-electrode map using computer keystrokes, and a visual representation of the frequency range employed by the filter bank is displayed on the monitor. The patient adjusts the frequency range interactively and selects the preferred setting in a much faster way than can be accomplished with commercially available hardware. If successful, this approach may be implemented in the next generation of hardware used to program cochlear implants in the clinic

We examined measures of oral and pharyngeal residues from scintigraphic studies and estimates/observations from videofluorographic (modified barium swallow) studies taken on the same day but not concurrently in 16 dysphagic patients of varying etiologies presenting with oral and/or pharyngeal dysphagia. Oral and pharyngeal residuals following the swallow were quantified scintigraphically and were then compared with measures of residuals obtained from the modified barium swallow. Estimates of oral and pharyngeal residues from the modified barium swallows were generated by a trained observer who was blinded to the scintigraphic data. Positive and significant Spearman correlations between oral and pharyngeal residue measures from scintigraphy and observations of oral and pharyngeal residues from modified barium swallows were found. This supports the validity of observations of oral and pharyngeal residues in clinical studies. Limitations of these observations are discussed

PURPOSE/OBJECTIVE:A multicenter, randomized study was undertaken to estimate the single agent activity of Tositumomab and to determine the contribution of radioisotope-labeling with (131)I to activity and toxicity by comparing treatment outcomes for Tositumomab and Iodine I 131 Tositumomab (BEXXAR) to an equivalent total dose of unlabeled Tositumomab. EXPERIMENTAL DESIGN/METHODS:Seventy-eight patients with refractory/relapsed non-Hodgkin's lymphoma were randomized to either unlabeled Tositumomab or Iodine I 131 Tositumomab. Patients progressing after unlabeled Tositumomab could cross over to receive Iodine I 131 Tositumomab. The median follow-up at analysis was 42.6 months (range 1.9 to 71.5 months). RESULTS:Responses in the Iodine I 131 Tositumomab versus unlabeled Tositumomab groups: overall response 55% versus 19% (P = 0.002); complete response 33% versus 8% (P = 0.012); median duration of overall response not reached versus 28.1 months (95% confidence interval: 7.6, not reached); median duration of complete response not reached in either arm; and median TTP 6.3 versus 5.5 months (P = 0.031), respectively. Of the patients who had a complete response after initial Iodine I 131 Tositumomab therapy, 71% (10 of 14) continued in complete response at 29.8 to 71.1 months. Two patients who achieved a complete response after unlabeled Tositumomab had ongoing responses at 48.1 to 56.9 months. Nineteen patients received Iodine I 131 Tositumomab crossover therapy. Responses after crossover versus prior response to unlabeled Tositumomab were as follows: complete response rates of 42% versus 0% (P = 0.008); overall response 68% versus 16% (P = 0.002); median durations of overall response 12.6 versus 7.6 months (P = 0.001); and median TTP 12.4 versus 5.5 months (P = 0.01), respectively. Hematologic toxicity was more severe and nonhematologic adverse events were more frequent after Iodine I 131 Tositumomab than after Tositumomab alone. Elevated thyrotropin occurred in 5% of patients. Seroconversion to human antimurine antibody after Iodine I 131 Tositumomab, unlabeled Tositumomab, and Iodine I 131 Tositumomab-crossover was 27%, 19%, and 0%, respectively. CONCLUSIONS:Unlabeled Tositumomab showed single agent activity, but in this direct comparison, all of the therapeutic outcome measures were significantly enhanced by the conjugation of (131)I to Tositumomab.